PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33593821-4	2021	Ritanserin, an inhibitor of diacylglycerol kinase alpha (DGKA), was identified as a selective inhibitor of proliferation of Tsc2-/- MEFs, with no impact on Tsc2+/+ MEFs.	Ritanserin	0-10	TSC complex subunit 2	Mus musculus	124-128	
33593821-6	2021	PA levels were increased 5-fold in Tsc2-/- MEFs compared to Tsc2+/+ MEFs, and treatment of Tsc2-/- MEFs with ritanserin led to depletion of PA as well as rewiring of phospholipid metabolism.	Ritanserin	109-119	TSC complex subunit 2	Mus musculus	35-39	
33593821-6	2021	PA levels were increased 5-fold in Tsc2-/- MEFs compared to Tsc2+/+ MEFs, and treatment of Tsc2-/- MEFs with ritanserin led to depletion of PA as well as rewiring of phospholipid metabolism.	Ritanserin	109-119	TSC complex subunit 2	Mus musculus	60-64	
33593821-6	2021	PA levels were increased 5-fold in Tsc2-/- MEFs compared to Tsc2+/+ MEFs, and treatment of Tsc2-/- MEFs with ritanserin led to depletion of PA as well as rewiring of phospholipid metabolism.	Ritanserin	109-119	TSC complex subunit 2	Mus musculus	60-64	
33593821-8	2021	Ritanserin decreased macropinocytic uptake of albumin, limited the number of lysosomes, and reduced lysosomal activity in Tsc2-/- MEFs.	Ritanserin	0-10	TSC complex subunit 2	Mus musculus	122-126